Objective:

To assess whether modern prostate cancer screening strategies can deliver benefits similar to those achieved by organized breast cancer screening programs.

Key Findings:

• Positive predictive value of biopsy for prostate cancer was 50-68%, significantly higher than 15% for breast screening.
• False-positive rates in prostate cancer screening were 37-42%, compared to about 10% in mammography.
• 69-74% of detected prostate cancers were clinically significant, similar to 73% for breast cancers.
• Detection of indolent tumors was slightly higher in prostate screening.

Interpretation:

The findings suggest that PSA testing, when integrated with MRI and selective biopsy, may provide population-level benefits comparable to mammography.

Limitations:

• The study's applicability may vary based on healthcare systems in different countries.
• Cost-effectiveness analysis of the new screening strategy compared to existing methods is still needed.

Conclusion:

The PROBASE trial indicates that a structured prostate cancer screening program can achieve performance metrics similar to established mammography programs, potentially reducing overtreatment through active surveillance.